Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 27;12(5):645.
doi: 10.3390/biom12050645.

Hepatocellular Carcinoma: The Role of MicroRNAs

Sharad Khare  1   2 , Tripti Khare  1 , Raghu Ramanathan  1   2 , Jamal A Ibdah  1   2   3
Affiliations
Review

Hepatocellular Carcinoma: The Role of MicroRNAs

Sharad Khare et al. Biomolecules. .

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. HCC is diagnosed in its advanced stage when limited treatment options are available. Substantial morphologic, genetic and epigenetic heterogeneity has been reported in HCC, which poses a challenge for the development of a targeted therapy. In this review, we discuss the role and involvement of several microRNAs (miRs) in the heterogeneity and metastasis of hepatocellular carcinoma with a special emphasis on their possible role as a diagnostic and prognostic tool in the risk prediction, early detection, and treatment of hepatocellular carcinoma.

Keywords: hepatocellular carcinoma; heterogeneity; metastasis; microRNA; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Venn diagram showing a list of microRNAs involved in HCC heterogeneity (19) and metastasis (33). Overlapping region shows microRNAs (4) that are common to both.
See this image and copyright information in PMC

References

    1. Gonzalez-Vallinas M., Breuhahn K. MicroRNAs are key regulators of hepatocellular carcinoma (HCC) cell dissemination-what we learned from microRNA-494. Hepatobiliary Surg. Nutr. 2016;5:372–376. doi: 10.21037/hbsn.2016.05.07. - DOI - PMC - PubMed
    1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005;55:74–108. doi: 10.3322/canjclin.55.2.74. - DOI - PubMed
    1. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005. J. Clin. Oncol. 2009;27:1485–1491. doi: 10.1200/JCO.2008.20.7753. - DOI - PMC - PubMed
    1. Friemel J., Rechsteiner M., Frick L., Bohm F., Struckmann K., Egger M., Moch H., Heikenwalder M., Weber A. Intratumor heterogeneity in hepatocellular carcinoma. Clin. Cancer Res. 2015;21:1951–1961. doi: 10.1158/1078-0432.CCR-14-0122. - DOI - PubMed
    1. Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–1978. doi: 10.1002/hep.23527. - DOI - PubMed

Publication types